Continued strong momentum in the Phase 3 registrational trial in adult patients with IH, with topline data anticipated in the fourth quarter of 2023. End-of-Phase 2 meeting with the U.S. Food and Drug Administration scheduled for late second quarter of 2023 to discuss the Prader-Willi Syndrome Phase 2 proof-of-concept study results and a proposed Phase 3 trial in patients with PWS. Enrollment continues in our Myotonic Dystrophy study. Anticipates topline data from this Phase 2 proof-of-concept trial in the fourth quarter of 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HRMY:
- Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
- 3 “Strong Buy” Stocks With Short Squeeze Potential
- HRMY Upcoming Earnings Report: What to Expect?
- Harmony Biosciences names Jeffrey Dayno, M.D as CEO
- BofA starts Harmony Biosciences at Neutral, sees downside risk to consensus
